The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Open accessAbstract
BACKGROUND: The direct oral thrombin inhibitor dabigatran has a predictable anticoagulant effect and may be an alternative therapy to warfarin for patients who have acute venous thromboembolism. METHODS: In a randomized, double-blind, noninferiority trial involving patients with acute venous thromboembolism who were initially given parenteral anticoagulation therapy for a median of 9 days (interquartile range, 8 to 11), we compared oral dabigatran, administered at a dose of 150 mg twice daily, with warfarin that was dose-adjusted to achieve an international normalized ratio of 2.0 to 3.0. The primary outcome was the 6-month incidence of recurrent symptomatic, objectively confirmed venous thromboembolism and related deaths. Safety end points included bleeding events, acute coronary syndromes, other adverse events, and results of liver-function tests. RESULTS: A total of 30 of the 1274 patients randomly assigned to receive dabigatran (2.4%), as compared with 27 of the 1265 patients randomly assigned to warfarin (2.1%), had recurrent venous thromboembolism; the difference in risk was 0.4 percentage points (95% confidence interval [CI], -0.8 to 1.5; P<0.001 for the prespecified noninferiority margin). The hazard ratio with dabigatran was 1.10 (95% CI, 0.65 to 1.84). Major bleeding episodes occurred in 20 patients assigned to dabigatran (1.6%) and in 24 patients assigned to warfarin (1.9%) (hazard ratio with dabigatran, 0.82; 95% CI, 0.45 to 1.48), and episodes of any bleeding were observed in 205 patients assigned to dabigatran (16.1%) and 277 patients assigned to warfarin (21.9%; hazard ratio with dabigatran, 0.71; 95% CI, 0.59 to 0.85). The numbers of deaths, acute coronary syndromes, and abnormal liver-function tests were similar in the two groups. Adverse events leading to discontinuation of the study drug occurred in 9.0% of patients assigned to dabigatran and in 6.8% of patients assigned to warfarin (P=0.05). CONCLUSIONS: For the treatment of acute venous thromboembolism, a fixed dose of dabigatran is as effective as warfarin, has a safety profile that is similar to that of warfarin, and does not require laboratory monitoring. (ClinicalTrials.gov number, NCT00291330.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Self-citationSCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Self-citationPharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
Antithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Antithrombotic Therapy for Venous Thromboembolic Disease
Kearon, C., Kahn, S. R., Agnelli, G., Goldhaber, S., Raskob, G. E., & Comerota, A. J. (2008) · Chest · doi:10.1378/chest.08-0658 · Cited by 1,996
Self-citationThe Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
Self-citationERIKSSON, B. I., DAHL, O. E., ROSENCHER, N., KURTH, A. A., VAN DIJK, C. N., FROSTICK, S. P., KÄLEBO, P., CHRISTIANSEN, A. V., HANTEL, S., HETTIARACHCHI, R., et al. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02748.x · Cited by 979
Self-citationSchulman, S., Rhedin, A.-S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P., Loogna, E., Svensson, E., Ljungberg, B., Walter, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506223322501 · Cited by 932
Self-citation
Cited by
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Self-citationAntithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Self-citationOral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Konstantinides, S. V., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu283 · Cited by 3,128
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Jaff, M. R., McMurtry, M. S., Archer, S. L., Cushman, M., Goldenberg, N., Goldhaber, S. Z., Jenkins, J. S., Kline, J. A., Michaels, A. D., Thistlethwaite, P., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318214914f · Cited by 2,229
Self-citationSteffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01647-2019 · Cited by 1,619
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Self-citationKaatz, S., Ahmad, D., Spyropoulos, A. C., & Schulman, S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13140 · Cited by 1,419
Self-citationStangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0758 · Cited by 1,382
Lyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Self-citationEerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,361
The Coagulopathy of Chronic Liver Disease
Tripodi, A., & Mannucci, P. M. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011170 · Cited by 1,342
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Pulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Self-citationAntithrombotic Therapy for VTE Disease
Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., Knighton, A. J., et al. (2021) · Chest · doi:10.1016/j.chest.2021.07.055 · Cited by 1,043
Self-citationDeep vein thrombosis and pulmonary embolism
Di Nisio, M., van Es, N., & Büller, H. R. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30514-1 · Cited by 994
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1113697 · Cited by 983
Self-citationTreatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Schulman, S., Kakkar, A. K., Goldhaber, S. Z., Schellong, S., Eriksson, H., Mismetti, P., Christiansen, A. V., Friedman, J., Le Maulf, F., Peter, N., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.004450 · Cited by 923
“events), urogenital (7), intracranial (2), intramuscular (1), and other (4).”
BackgroundSelf-citationManagement of severe perioperative bleeding: Guidelines from the European Society of Anaesthesiology
Kozek-Langenecker, S. A., Afshari, A., Albaladejo, P., Santullano, C. A. A., De Robertis, E., Filipescu, D. C., Fries, D., Görlinger, K., Haas, T., Imberger, G., et al. (2013) · European Journal of Anaesthesiology · doi:10.1097/eja.0b013e32835f4d5b · Cited by 909
van Es, N., Coppens, M., Schulman, S., Middeldorp, S., & Büller, H. R. (2014) · Blood · doi:10.1182/blood-2014-04-571232 · Cited by 851
Self-citationRuiz-Irastorza, G., Crowther, M., Branch, W., & Khamashta, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60709-x · Cited by 831
Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement
Lassen, M. R., Gallus, A., Raskob, G. E., Pineo, G., Chen, D., & Ramirez, L. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006885 · Cited by 775
Kakkos, S. K., Gohel, M., Baekgaard, N., Bauersachs, R., Bellmunt-Montoya, S., Black, S. A., ten Cate-Hoek, A. J., Elalamy, I., Enzmann, F. K., Geroulakos, G., et al. (2021) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2020.09.023 · Cited by 743
Lyman, G. H., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., Gates, L. E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1118 · Cited by 713
Self-citationFrontera, J. A., Lewin III, J. J., Rabinstein, A. A., Aisiku, I. P., Alexandrov, A. W., Cook, A. M., del Zoppo, G. J., Kumar, M. A., Peerschke, E. I. B., Stiefel, M. F., et al. (2016) · Neurocritical Care · doi:10.1007/s12028-015-0222-x · Cited by 706
Time Trends in Pulmonary Embolism in the United States: Evidence of Overdiagnosis
Wiener, R. S., Schwartz, L. M., & Woloshin, S. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.178 · Cited by 651
Farge, D., Frere, C., Connors, J. M., Ay, C., Khorana, A. A., Munoz, A., Brenner, B., Kakkar, A., Rafii, H., Solymoss, S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30336-5 · Cited by 651
Self-citationAujesky, D., Roy, P.-M., Verschuren, F., Righini, M., Osterwalder, J., Egloff, M., Renaud, B., Verhamme, P., Stone, R. A., Legall, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60824-6 · Cited by 598
The Hemostatic System as a Modulator of Atherosclerosis
Borissoff, J. I., Spronk, H. M. H., & ten Cate, H. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011670 · Cited by 569
Prins, M. H., Lensing, A. W., Bauersachs, R., van Bellen, B., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., Raskob, G. E., et al. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-21 · Cited by 551
Coagulation and cancer: biological and clinical aspects
FALANGA, A., MARCHETTI, M., & VIGNOLI, A. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12075 · Cited by 551
van der Hulle, T., Kooiman, J., den Exter, P. L., Dekkers, O. M., Klok, F. A., & Huisman, M. V. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12485 · Cited by 536
Epidemiology and prevention of venous thromboembolism
Lutsey, P. L., & Zakai, N. A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00787-6 · Cited by 507
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
Martin, K., Beyer‐Westendorf, J., Davidson, B. L., Huisman, M. V., Sandset, P. M., & Moll, S. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13323 · Cited by 445
Complications of intracerebral haemorrhage
Balami, J. S., & Buchan, A. M. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70264-2 · Cited by 444
Agnelli, G., & Becattini, C. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0907731 · Cited by 444
Miller, C. S., Grandi, S. M., Shimony, A., Filion, K. B., & Eisenberg, M. J. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.03.049 · Cited by 432
Uchino, K. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.1666 · Cited by 431
Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
Freeman, J. V., Zhu, R. P., Owens, D. K., Garber, A. M., Hutton, D. W., Go, A. S., Wang, P. J., & Turakhia, M. P. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-1-201101040-00289 · Cited by 429
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Akl, E. A., Kahale, L. A., Barba, M., Neumann, I., Labedi, N., Terrenato, I., Sperati, F., Muti, P., & Schünemann, H. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006650.pub4 · Cited by 428
Yao, X., Abraham, N. S., Sangaralingham, L. R., Bellolio, M. F., McBane, R. D., Shah, N. D., & Noseworthy, P. A. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003725 · Cited by 419
Holster, I. L., Valkhoff, V. E., Kuipers, E. J., & Tjwa, E. T. T. L. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.041 · Cited by 408
Mekaj, A., Mekaj, Y., Duci, S., & Miftari, E. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s84210 · Cited by 407
Dahl, O., Huo, M., Kurth, A., Hantel, S., Hermansson, K., Schnee, J., Friedman, R., Eriksson, B., & for the RE-NOVATE II Study Group (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-10-0679 · Cited by 401
Self-citationManagement of venous thrombo-embolism: an update
Konstantinides, S., & Torbicki, A. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu243 · Cited by 383
Deep vein thrombosis: pathogenesis, diagnosis, and medical management
Stone, J., Hangge, P., Albadawi, H., Wallace, A., Shamoun, F., Knuttien, M. G., Naidu, S., & Oklu, R. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.09.01 · Cited by 381
Wolberg, A. S., Rosendaal, F. R., Weitz, J. I., Jaffer, I. H., Agnelli, G., Baglin, T., & Mackman, N. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.6 · Cited by 369
Dabigatran Etexilate: A New Oral Thrombin Inhibitor
Hankey, G. J., & Eikelboom, J. W. (2011) · Circulation · doi:10.1161/circulationaha.110.004424 · Cited by 348
Farge, D., Bounameaux, H., Brenner, B., Cajfinger, F., Debourdeau, P., Khorana, A. A., Pabinger, I., Solymoss, S., Douketis, J., & Kakkar, A. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30369-2 · Cited by 347
Self-citationGuidance for the treatment of deep vein thrombosis and pulmonary embolism
Streiff, M. B., Agnelli, G., Connors, J. M., Crowther, M., Eichinger, S., Lopes, R., McBane, R. D., Moll, S., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1317-0 · Cited by 344
Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
Shah, S. V., & Gage, B. F. (2011) · Circulation · doi:10.1161/circulationaha.110.985655 · Cited by 337
Huisman, M. V., Barco, S., Cannegieter, S. C., Le Gal, G., Konstantinides, S. V., Reitsma, P. H., Rodger, M., Noordegraaf, A. V., & Klok, F. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.28 · Cited by 336
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
Burnett, A. E., Mahan, C. E., Vazquez, S. R., Oertel, L. B., Garcia, D. A., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1310-7 · Cited by 333
Management of Pulmonary Embolism
Konstantinides, S. V., Barco, S., Lankeit, M., & Meyer, G. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.061 · Cited by 330
Chai-Adisaksopha, C., Crowther, M., Isayama, T., & Lim, W. (2014) · Blood · doi:10.1182/blood-2014-07-590323 · Cited by 326
Robert, S., Chatelain, C., Douxfils, J., Mullier, F., Chatelain, B., & Dogné, J.-M. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-11-0804 · Cited by 325
Erkan, D., Aguiar, C. L., Andrade, D., Cohen, H., Cuadrado, M. J., Danowski, A., Levy, R. A., Ortel, T. L., Rahman, A., Salmon, J. E., et al. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.053 · Cited by 322
Glund, S., Stangier, J., Schmohl, M., Gansser, D., Norris, S., van Ryn, J., Lang, B., Ramael, S., Moschetti, V., Gruenenfelder, F., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60732-2 · Cited by 319
National Trends in Oral Anticoagulant Use in the United States, 2007 to 2011
Kirley, K., Qato, D. M., Kornfield, R., Stafford, R. S., & Alexander, G. C. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.967299 · Cited by 311
Ferro, J. M., Coutinho, J. M., Dentali, F., Kobayashi, A., Alasheev, A., Canhão, P., Karpov, D., Nagel, S., Posthuma, L., Roriz, J. M., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2764 · Cited by 311
Pernod, G., Albaladejo, P., Godier, A., Samama, C. M., Susen, S., Gruel, Y., Blais, N., Fontana, P., Cohen, A., Llau, J. V., et al. (2013) · Archives of Cardiovascular Diseases · doi:10.1016/j.acvd.2013.04.009 · Cited by 309
Self-citationThe pharmacological landscape and therapeutic potential of serine hydrolases
Bachovchin, D. A., & Cravatt, B. F. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3620 · Cited by 308
Acute Pulmonary Embolism: A Review
Freund, Y., Cohen-Aubart, F., & Bloom, B. (2022) · JAMA · doi:10.1001/jama.2022.16815 · Cited by 301
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
Perzborn, E., Roehrig, S., Straub, A., Kubitza, D., & Misselwitz, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3185 · Cited by 297
Veitch, A. M., Vanbiervliet, G., Gershlick, A. H., Boustiere, C., Baglin, T. P., Smith, L.-A., Radaelli, F., Knight, E., Gralnek, I. M., Hassan, C., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-311110 · Cited by 296
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
Majeed, A., Hwang, H.-G., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Wallentin, L., Brueckmann, M., Fraessdorf, M., Yusuf, S., & Schulman, S. (2013) · Circulation · doi:10.1161/circulationaha.113.002332 · Cited by 277
Self-citationLee, C. J., & Ansell, J. E. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03916.x · Cited by 272
Direct Oral Anticoagulants in Patients With VTE and Cancer
Vedovati, M. C., Germini, F., Agnelli, G., & Becattini, C. (2015) · Chest · doi:10.1378/chest.14-0402 · Cited by 270
Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays
Baghaei, F., Blixter, I. F., Gustafsson, K., Stigendal, L., Sten-Linder, M., Strandberg, K., Hillarp, A., Lindahl, T., & and from the expert group on coagulation of the External Quality Assurance in Laboratory Medicine in Sweden (2011) · Thrombosis and Haemostasis · doi:10.1160/th10-06-0342 · Cited by 269
Left Ventricular Thrombus After Acute Myocardial Infarction: Screening, Prevention, and Treatment
McCarthy, C. P., Vaduganathan, M., McCarthy, K. J., Januzzi, J. L., Bhatt, D. L., & McEvoy, J. W. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.1086 · Cited by 268
Lankeit, M., Jiménez, D., Kostrubiec, M., Dellas, C., Hasenfuss, G., Pruszczyk, P., & Konstantinides, S. (2011) · Circulation · doi:10.1161/circulationaha.111.051177 · Cited by 266
Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration
Simes, J., Becattini, C., Agnelli, G., Eikelboom, J. W., Kirby, A. C., Mister, R., Prandoni, P., & Brighton, T. A. (2014) · Circulation · doi:10.1161/circulationaha.114.008828 · Cited by 262
Time Trends In Pulmonary Embolism In The United States: Evidence Of Overdiagnosis?
Wiener, R., Schwartz, L., & Woloshin, S. (2010) · D14. INNOVATIVE HEALTH SERVICES RESEARCH TO IMPROVE OUTCOMES · doi:10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5348 · Cited by 256
Couturaud, F., Sanchez, O., Pernod, G., Mismetti, P., Jego, P., Duhamel, E., Provost, K., dit Sollier, C. B., Presles, E., Castellant, P., et al. (2015) · JAMA · doi:10.1001/jama.2015.7046 · Cited by 249
Self-citationGoldhaber, S. Z., Eriksson, H., Kakkar, A., Schellong, S., Feuring, M., Fraessdorf, M., Kreuzer, J., Schueler, E., & Schulman, S. (2016) · Vascular Medicine · doi:10.1177/1358863x16668588 · Cited by 89
Self-citationNathan, A. S., Geng, Z., Dayoub, E. J., Khatana, S. A. M., Eberly, L. A., Kobayashi, T., Pugliese, S. C., Adusumalli, S., Giri, J., & Groeneveld, P. W. (2019) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.119.005600 · Cited by 67
Moudallel, S., Steurbaut, S., Cornu, P., & Dupont, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01220 · Cited by 65
How I treat recurrent venous thromboembolism in patients receiving anticoagulant therapy
Schulman, S. (2017) · Blood · doi:10.1182/blood-2017-03-742304 · Cited by 62
Self-citationGómez-Outes, A., Lecumberri, R., Suárez-Gea, M. L., Terleira-Fernández, A.-I., Monreal, M., & Vargas-Castrillón, E. (2015) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248415575154 · Cited by 57
Lutsey, P. L., Zakai, N. A., MacLehose, R. F., Norby, F. L., Walker, R. F., Roetker, N. S., Adam, T. J., & Alonso, A. (2019) · British Journal of Haematology · doi:10.1111/bjh.15857 · Cited by 47
Preblick, R., Kwong, W. J., White, R. H., & Goldhaber, S. Z. (2015) · Hospital Practice · doi:10.1080/21548331.2015.1099412 · Cited by 28
“[38–40] There is also wide variation in treatment duration, the proportion of unprovoked/provoked VTE cases, the number of PE patients and the disease extensiveness that were studied in the Phase 3 clinical trials.”
BackgroundSelf-citationLanitis, T., Leipold, R., Hamilton, M., Rublee, D., Quon, P., Browne, C., & Cohen, A. T. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.01.020 · Cited by 23
Amin, A., Jing, Y., Trocio, J., Lin, J., Lingohr-Smith, M., & Graham, J. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.950670 · Cited by 22
Sindet-Pedersen, C., Pallisgaard, J. L., Olesen, J. B., Gislason, G. H., & Arevalo, L. C. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.022 · Cited by 22
Amin, A., Bruno, A., Trocio, J., Lin, J., & Lingohr-Smith, M. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615585991 · Cited by 20
Quon, P., Le, H. H., Raymond, V., Mtibaa, M., & Moshyk, A. (2016) · Journal of Medical Economics · doi:10.3111/13696998.2016.1141780 · Cited by 12
Jugrin, A. V., Ustyugova, A., Urbich, M., Sunderland, T., & Lamotte, M. (2015) · Thrombosis and Haemostasis · doi:10.1160/th14-12-1027 · Cited by 11
Drug therapy in anticoagulation: which drug for which patient?
Millar, C. M., & Laffan, M. A. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-3-233 · Cited by 11
Kumbhani, D. J., Armbruster, A. L., Cheng, R. K., Chrispin, J., Fischer, U., Holbrook, A. M., Joglar, J., & Sevestre, M.-A. (2026) · JACC · doi:10.1016/j.jacc.2026.05.033 · Cited by 2
Metadata
- Authors
- Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-10
- Volume
- 361
- Issue
- 24
- Pages
- 2342-2352
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118092611
- Cited by
- 2,583
- References
- 28
- FWCI
- 107.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.